AlphaFold predicted structure
MASTL · Q96GX5

Mean pLDDT
54.2/ 100
Low
879 residues
Confidence breakdown
- Very high(≥ 90)20%
- Confident(70–90)13%
- Low(50–70)7%
- Very low(< 50)60%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
microtubule associated serine/threonine kinase like
Annotations refreshed 9 hours ago.
Moderate Evidence (Amber)
Cytopenia - NOT Fanconi anaemia
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownCytopenias and congenital anaemias
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownneurodegenerative disease
multiple sclerosis
Parkinson disease
lysosomal storage disease
Alzheimer disease
autosomal thrombocytopenia with normal platelets
Thrombocytopenia
severe aplastic anemia
congenital anomaly of cardiovascular system
thrombocytopenia 2
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Serine/threonine-protein kinase greatwall
Serine/threonine kinase that plays a key role in M phase by acting as a regulator of mitosis entry and maintenance (PubMed:19680222). Acts by promoting the inactivation of protein phosphatase 2A (PP2A) during M phase: does not directly inhibit PP2A but acts by mediating phosphorylation and subsequent activation of ARPP19 and ENSA at 'Ser-62' and 'Ser-67', respectively (PubMed:38123684). ARPP19 and ENSA are phosphatase inhibitors that specifically inhibit the PPP2R2D (PR55-delta) subunit of PP2A. Inactivation of PP2A during M phase is essential to keep cyclin-B1-CDK1 activity high (PubMed:20818157). Following DNA damage, it is also involved in checkpoint recovery by being inhibited. Phosphorylates histone protein in vitro; however such activity is unsure in vivo. May be involved in megakaryocyte differentiation
MASTL · Q96GX5

Mean pLDDT
54.2/ 100
Low
879 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0